Technical Analysis for ARCT - Arcturus Therapeutics Ltd.

Grade Last Price % Change Price Change
F 27.33 -0.44% -0.12
ARCT closed down 0.44 percent on Monday, June 24, 2024, on 74 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
6 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Slingshot Bearish Bearish Swing Setup -0.44%
Wide Bands Range Expansion -0.44%
Oversold Stochastic Weakness -0.44%
Volume Surge Other 2.78%
NR7 Range Contraction 2.78%
Wide Bands Range Expansion 2.78%
Oversold Stochastic Weakness 2.78%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 15 hours ago
Down 2 % about 19 hours ago
60 Minute Opening Range Breakdown about 19 hours ago
Down 1% about 19 hours ago
Rose Above Previous Day's High about 19 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Arcturus Therapeutics Ltd. Description

Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine. MDX consists of a single bi-layer oral tablet, which includes both a rapid onset release metadoxine formulation and a slow release metadoxine formulation together providing the desired dual release profile. The new extended-release formulation prolongs the human plasma levels of metadoxine for up to 12 hours, which results in enhanced efficacy benefits. ADAIR is an oral, semi-solid, liquid-filled, hard gelatin capsule of an abuse-deterrent IR formulation of dextroamphetamine sulfate, which is manufactured as 10 mg capsules.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Health Sciences Drugs Pharmacology Euphoriants Amphetamine Cognitive Disorders Glutamate Tablet Adhd Taar1 Agonists

Is ARCT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 45.0
52 Week Low 17.5238
Average Volume 598,925
200-Day Moving Average 29.74
50-Day Moving Average 30.47
20-Day Moving Average 33.85
10-Day Moving Average 29.34
Average True Range 2.57
RSI (14) 39.76
ADX 28.11
+DI 22.08
-DI 31.16
Chandelier Exit (Long, 3 ATRs) 37.28
Chandelier Exit (Short, 3 ATRs) 32.92
Upper Bollinger Bands 45.17
Lower Bollinger Band 22.54
Percent B (%b) 0.21
BandWidth 66.87
MACD Line -1.37
MACD Signal Line -0.17
MACD Histogram -1.2009
Fundamentals Value
Market Cap 730.35 Million
Num Shares 26.7 Million
EPS 3.76
Price-to-Earnings (P/E) Ratio 7.27
Price-to-Sales 3.75
Price-to-Book 3.78
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 29.34
Resistance 3 (R3) 29.36 28.70 29.01
Resistance 2 (R2) 28.70 28.19 28.70 28.89
Resistance 1 (R1) 28.02 27.88 27.69 28.00 28.78
Pivot Point 27.36 27.36 27.20 27.36 27.36
Support 1 (S1) 26.68 26.85 26.35 26.66 25.88
Support 2 (S2) 26.02 26.54 26.02 25.77
Support 3 (S3) 25.34 26.02 25.66
Support 4 (S4) 25.32